Nasdaq:PGEN
PRECIGEN, INC.
PRECIGEN leverages proprietary genomic technologies to advance precision oncology and rare disease diagnostics for the life sciences market.
Key Metrics
Investment Thesis
Bull Case
Despite current headwinds, PGEN possesses valuable intellectual property in the high-growth rare disease and precision oncology sectors that could drive future licensing revenue. The company's strong cash position of $48.6M ending balance provides a runway to navigate restructuring costs and invest in next-generation sequencing technologies. If management can successfully pivot operations away from discontinued segments, the underlying technology platform offers significant upside potential in the crowded genomics market.
Bear Case
The core business is struggling with negative operating cash flow and substantial losses before tax, suggesting the current revenue model may not be self-sustaining without external financing. The massive $155.3M cash outflow from financing activities and reliance on discontinued ops profits create an unstable earnings profile that investors should avoid. With retained earnings deficits exceeding $1.8B, the company has limited internal capital reserves to weather prolonged periods of low biotech investment.
About PRECIGEN, INC.
PRECIGEN, Inc. (PGEN) develops and commercializes proprietary technologies for the life sciences sector, primarily focusing on precision oncology and genetic testing solutions. The company serves global markets including cancer research, diagnostics, and personalized medicine development through its specialized platforms. Key products leverage advanced genomic sequencing and computational biology to address unmet needs in rare disease and oncology treatment.
Analysis
Management Discussion
While the company reported a net profit of $28.3M, this figure is largely attributable to significant gains from discontinued operations totaling $108.1M rather than organic growth from core activities. Continuing operations generated an operating loss of $80.0M and negative cash flow from operations of $65.0M, indicating substantial ongoing operational challenges. The balance sheet reflects a complex restructuring phase with net fixed assets declining to $7.3M and significant non-cash adjustments exceeding $92M.
Industry Overview
The life sciences sector is experiencing rapid innovation in genomic sequencing, but funding remains volatile as private equity and venture capital pull back from late-stage development. Companies specializing in rare diseases face high R&D costs and long regulatory approval timelines that can strain cash reserves before commercialization. The market rewards firms with proprietary data advantages and strong commercial partnerships, penalizing those with thin margins and heavy reliance on grant funding.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 |
|---|---|
| Revenue | $26.9M |
| Cost of Revenue | $0 |
| Gross Profit | $26.9M |
| Operating Expenses | $106.9M |
| Operating Income | $-80.0M |
| Stock-Based Comp | $10.2M |
| D&A | $10.8M |
| Depreciation | $2.4M |
| Amortization | $4.8M |
| Non-Operating Income | $0 |
| Pre-Tax Income | $-80.0M |
| Income Tax | $-189.0K |
| Continuing Ops | $-79.8M |
| Discontinued Ops | $108.1M |
| Net Income | $28.3M |
| Minority Interest | $0 |
| Net to Common | $28.3M |
| Metric | 2022 |
|---|---|
| Current Assets | $118.2M |
| Cash & Equivalents | $4.9M |
| Marketable Securities | $51.1M |
| Accounts Receivable | $959.0K |
| Prepaid Expenses | $4.8M |
| Other Current Assets | $56.5M |
| Long-Term Assets | $97.8M |
| PP&E (Net) | $7.3M |
| Intangibles | $44.5M |
| Goodwill | $36.9M |
| Operating Leases | $8.1M |
| Other LT Assets | $1.0M |
| Total Assets | $216.0M |
| Current Liabilities | $78.6M |
| Accounts Payable | $4.1M |
| Current Debt | $43.2M |
| Current Leases | $1.2M |
| Deferred Revenue | $25.0K |
| Other Current Liab | $30.1M |
| Long-Term Liabilities | $11.1M |
| Long-Term Debt | $0 |
| LT Operating Leases | $7.0M |
| Other LT Liab | $2.3M |
| Total Liabilities | $89.7M |
| Shareholders' Equity | $126.3M |
| Paid-In Capital | $2.00B |
| Retained Earnings | $-1.87B |
| AOCI | $-3.5M |
| Total L&E | $216.0M |
| Metric | 2022 |
|---|---|
| Net Income (CFO) | $28.3M |
| Non-Cash Adjustments | $-92.6M |
| Working Capital Changes | $-731.0K |
| Cash from Operations | $-65.0M |
| Capital Expenditures | $4.9M |
| Cash from Investing | $226.4M |
| Debt Repayments | $154.7M |
| Cash from Financing | $-155.3M |
| FX Effect | $-827.0K |
| Net Change in Cash | $5.3M |
| Beginning Cash | $43.3M |
| Ending Cash | $48.6M |
Frequently Asked Questions
How does PRECIGEN, INC. make money?
The company's revenue is driven by its core technology platforms serving academic research institutions, biopharmaceutical partners, and clinical trial participants. Primary segments include precision oncology solutions that facilitate cancer research and patient stratification, alongside genetic testing services for rare disease identification and validation. Additional streams involve licensing intellectual property and providing specialized data analytics tools to support drug discovery pipelines.
What are the main risks for PGEN?
Investors face significant risk due to the company's substantial cash burn from operations combined with massive one-time financing outflows related to divestitures or restructuring. The heavy reliance on discontinued operations for reported profitability masks the underlying weakness in continuing core business operations, creating sustainability concerns. Fluctuations in biotechnology funding cycles and potential regulatory hurdles for genetic testing products could further impact future revenue growth.
What is PGEN's competitive advantage?
PRECIGEN holds a strong moat through proprietary genomic datasets and validated algorithms that differentiate its precision medicine offerings from generic competitors. The company benefits from deep partnerships with leading pharmaceutical giants and academic centers, securing first-mover advantages in emerging therapeutic areas. High barriers to entry are maintained by the specialized expertise required for rare disease genomics and the extensive validation of their computational platforms.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.